For news outlets covering the solanezumab Alzheimer’s drug trial results:
Mayo Clinic Alzheimer’s expert and neurologist Ronald Petersen, M.D. sees good news and bad news in the trial results announced today, regarding the Eli Lilly Alzheimer’s drug, solanezumab.
MP3 audio clips and a photo of Dr. Petersen are available in the downloads above; transcripts of the sound bites are below.
Dr. Petersen is a neurologist with Mayo Clinic in Rochester, Minn., chair of the federal Advisory Council on Alzheimer's Research, Care and Services and a leader in drafting the first U.S. national plan to address Alzheimer’s disease.
To interview Dr. Petersen, please contact:
Sound bite #1: “It’s a soft finding at this point in time. It’s a bit subtle, but it seems to be real and it may in fact mean that the drug is doing what it’s supposed to do, but the conundrum in the field remains that treating patients with established dementia due to Alzheimer’s disease may be too late, so we may be in fact trying to intervene after sufficient damage is done in the brain that we really cannot reverse it.”
Sound bite #2: “All of these studies have incorporated imaging markers, spinal fluid markers, blood markers into the design of the study such that as the patients were treated with these various antibodies, certain biological signals were measured as well. And it may very well be that that’s where the money lies in these studies. That is, if in fact the biomarkers are moving in the direction which one would expect based on treatment with these antibodies.”